VEGF: Driving Innovation in Oncology, Ophthalmology, and Regeneration

With rapid advances in biopharmaceuticals, vascular endothelial growth factor (VEGF) has emerged as a pivotal target across a wide range of disease pathways, driving the evolution of modern therapeutic strategies. Under physiological conditions, VEGF maintains vascular homeostasis by regulating angiogenesis and tissue repair. When dysregulated, however, it becomes a key driver of pathology—promoting tumor angiogenesis and progression in cancer, and fueling choroidal neovascularization and vision loss in ocular diseases. Targeting the VEGF signaling pathway has already delivered transformative clinical benefits in oncology and ophthalmology, while its growing relevance in tissue regeneration and aging-related disorders is opening new frontiers for research and therapy.

A New Paradigm in Cancer Therapy: PD-1/VEGF Combinations Push the Boundaries of Oncology

The tumor microenvironment (TME) plays a central role in cancer progression and metastasis, with the VEGF signaling pathway serving as a key regulator of both tumor angiogenesis and immune evasion. By driving aberrant vascularization and epithelial–mesenchymal transition (EMT), VEGF fuels tumor growth, immunosuppression, and metastatic spread ^[1], making it a critical and highly validated therapeutic target.